LIVN
LivaNova PLC+14.13 (+17.69%) TodayNov 4, 10:44 AM ET
About LIVN
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Company
- Headquarters
- Gloucester
- Employees
- 3,300 (2026)
- Listed
- Feb 10, 1993
- Exchange
- Nasdaq
- Website
- livanova.com
- SEC industry
- Electromedical & Electrotherapeutic Apparatus
- Cylvex sector
- Health Care · Medical Devices
Medical Devices
- Market cap #30 of 163
- P/B #71 of 152
Ranked highest first among stocks Cylvex covers.
- ABTAbbott Laboratories$197.4B+4.29%
- ISRGIntuitive Surgical Inc$168.9B+8.46%
- MDTMedtronic plc$133.5B+5.55%
- SYKStryker Corporation$127.8B+7.31%
- BSXBoston Scientific Corp.$66.40B+5.32%
Financial summary
Related companies
About
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.